News Sentiment

VRCA sentiment intelligence

Verrica Pharmaceuticals Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 55 Balanced news tone 67 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 5.59 Week of 17 Jul 2026
Weighted tone 55/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

75/100 classification confidence.

Company focus 58

directly relevant articles

Source quality 2

high-authority source matches

Trend context Trend inactive

-10.7% over one week, -0.7% over four weeks, trend inactive, and below fair value.

Latest direct headline Neutral

Verrica Pharmaceuticals Signs Distribution Deal With Medomie for Molluscum Treatment

Market Reaction

Price moving ahead of tone

62/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 75/100 classification
One-week reaction -10.7% Price reacting lower
Trend fit Trend inactive -0.7% over four weeks
Fair value -77.9% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 18
Neutral 42
Negative 7

Relevance

Why the article matched

Direct first
Direct company coverage 58
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
TradingView 13
Market source 8
dars.gov.et 6
Stock Titan 4
GlobeNewswire 4
TradingKey 4
simplywall.st 3
MT Newswires 2

Event Lens

What the news is about

Classified themes
Earnings 30
Market update 28
Regulatory and legal 4
Balance sheet 3
Deals and strategy 1
Analyst action 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 67
Stock Titan Direct company coverage

Verrica deal could bring YCANTH to Israeli children if approved

Verrica Pharmaceuticals has signed an exclusive distribution, marketing, and supply agreement with Medomie Pharma to commercialize YCANTH for molluscum contagiosum in Israel. While Medomie will seek regulatory approval and distribute the product, Verrica will manufacture and supp

Tone
Positive 92/100
Event
Regulatory and legal
Published
21 Jul 2026 11:40
Source
Stock Titan
The Manila Times Direct company coverage

Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel

Verrica Pharmaceuticals and Medomie Pharma have entered an exclusive distribution, marketing, and supply agreement to commercialize YCANTH® for molluscum contagiosum in Israel. Medomie will seek regulatory approval and distribute the product, while Verrica manufactures YCANTH and

Tone
Positive 75/100
Event
Regulatory and legal
Published
21 Jul 2026 11:40
Source
The Manila Times
AD HOC NEWS Direct company coverage

Verrica Pharmaceuticals holds the spotlight after recent market context

Verrica Pharmaceuticals (VRCA) is highlighted for its Nasdaq listing and SEC reporting, with its commercial product YCANTH, a prescription treatment for molluscum contagiosum, being its primary revenue driver. Investors are encouraged to focus on the company's filings, investor m

Tone
Neutral 50/100
Event
Earnings
Published
07 Jul 2026 18:10
Source
AD HOC NEWS
GuruFocus Direct company coverage

Q1 2026 Verrica Pharmaceuticals Inc Earnings Call Transcript

Verrica Pharmaceuticals Inc. reported a 25.4% increase in U.S. Ycanth product revenue for Q1 2026, alongside the launch of Wycanth in Japan, signifying global expansion. The company is actively progressing its Phase III common warts program and achieved a strong gross product mar

Tone
Positive 61/100
Event
Earnings
Published
05 Jul 2026 09:11
Source
GuruFocus
Finviz Direct company coverage

VRCA - Verrica Pharmaceuticals Inc Latest SEC Filings

This article provides detailed financial and stock performance data for Verrica Pharmaceuticals Inc. (VRCA), including its latest market capitalization, income, sales, insider ownership, institutional ownership, and various profitability and growth metrics. It also lists the comp

Tone
Neutral 50/100
Event
Market update
Published
04 Jul 2026 09:09
Source
Finviz
www.marketscreener.com Direct company coverage

Verrica Pharmaceuticals Inc.(NasdaqCM:VRCA) added to Russell Microcap Growth Benchmark Index

Verrica Pharmaceuticals Inc. (NasdaqCM: VRCA) has been added to the Russell Microcap Growth Benchmark Index, which is based on Friday's closing market values. This inclusion indicates the company's strong growth potential and increased visibility within the financial markets. The

Tone
Positive 69/100
Event
Market update
Published
29 Jun 2026 19:39
Source
www.marketscreener.com
marketscreener.com Direct company coverage

Verrica Pharmaceuticals Inc.(NasdaqCM:VRCA) added to Russell 3000E Growth Benchmark

Verrica Pharmaceuticals Inc. (NasdaqCM:VRCA) has been added to the Russell 3000E Growth Benchmark. The company specializes in dermatology therapeutics, developing and selling medications for skin diseases, with its commercial product YCANTH (VP-102) for molluscum contagiosum and

Tone
Positive 66/100
Event
Market update
Published
29 Jun 2026 08:41
Source
marketscreener.com
www.marketscreener.com Direct company coverage

Verrica Pharmaceuticals Inc.(NasdaqCM: VRCA) added to Russell Microcap Index

Verrica Pharmaceuticals Inc. (NasdaqCM: VRCA) has been added to the Russell Microcap Index. The company is a dermatology therapeutics firm focused on developing and selling medications for skin diseases, with its primary product YCANTH (VP-102) approved for molluscum contagiosum

Tone
Positive 71/100
Event
Market update
Published
29 Jun 2026 05:39
Source
www.marketscreener.com
TradingView Direct company coverage

Price to earnings ratio of Verrica Pharmaceuticals Inc. – DUS:1NE0

This article focuses solely on the price-to-earnings ratio of Verrica Pharmaceuticals Inc. (DUS:1NE0), a company listed on the Dusseldorf Stock Exchange. It appears to be a stub or a data placeholder, as no specific financial figures or analyses of the ratio are provided within t

Tone
Neutral 50/100
Event
Earnings
Published
28 Jun 2026 11:10
Source
TradingView
TradingView Direct company coverage

Enterprise value to revenue forward of Verrica Pharmaceuticals Inc. – NASDAQ:VRCA

This article provides a financial statistic for Verrica Pharmaceuticals Inc. (NASDAQ: VRCA), specifically its enterprise value to revenue forward. The content is primarily a data point presented within the TradingView platform, with no additional textual analysis or details provi

Tone
Neutral 50/100
Event
Earnings
Published
28 Jun 2026 08:10
Source
TradingView
TradingView Direct company coverage

Number of shareholders of Verrica Pharmaceuticals Inc. – DUS:1NE0

This article focuses on Verrica Pharmaceuticals Inc. (DUS:1NE0), specifically regarding its number of shareholders. It appears to be a stub or a data point from a financial platform like TradingView, indicating that specific shareholder figures are available for the company. The

Tone
Neutral 50/100
Event
Market update
Published
28 Jun 2026 06:39
Source
TradingView
TradingView Direct company coverage

Enterprise value to EBITDA forward of Verrica Pharmaceuticals Inc. – NASDAQ:VRCA

The article focuses on the enterprise value to EBITDA forward for Verrica Pharmaceuticals Inc. (NASDAQ: VRCA). It appears to be a financial data page rather than a detailed news article, highlighting the specific financial metric for the company.

Tone
Neutral 50/100
Event
Market update
Published
27 Jun 2026 21:10
Source
TradingView
TradingView Direct company coverage

Enterprise value to EBIT forward of Verrica Pharmaceuticals Inc. – NASDAQ:VRCA

This article provides financial information for Verrica Pharmaceuticals Inc. (NASDAQ: VRCA), specifically focusing on its enterprise value to EBIT forward. It presents this data within the TradingView platform context, indicating market closure and no recent trades. The content p

Tone
Neutral 50/100
Event
Market update
Published
27 Jun 2026 14:39
Source
TradingView
TradingView Direct company coverage

Verrica Pharmaceuticals Inc. Cash Flow – DUS:1NE0

This article provides details on the cash flow of Verrica Pharmaceuticals Inc. (DUS:1NE0), listed on the Dusseldorf Stock Exchange. It highlights that the free cash flow for Q1 2026 was -7.93M EUR, and for 2025, it was -15.10M EUR with the same operating cash flow. The data cover

Tone
Neutral 50/100
Event
Balance sheet
Published
27 Jun 2026 13:39
Source
TradingView
TradingView Direct company coverage

Enterprise value to revenue forward of Verrica Pharmaceuticals Inc. – DUS:1NE0

This article provides financial information for Verrica Pharmaceuticals Inc. (DUS:1NE0), specifically focusing on its enterprise value to forward revenue. It indicates that no trades have occurred for the stock, and the market is currently closed. The content is primarily a data

Tone
Neutral 50/100
Event
Earnings
Published
27 Jun 2026 11:39
Source
TradingView
TradingView Direct company coverage

VRCA Forecast — Price Target — Prediction for 2027

This article provides a forecast for Verrica Pharmaceuticals Inc. (VRCA) stock, including analyst price targets and predictions for 2027. It details recent stock performance, historical highs and lows, financial metrics like revenue and earnings, and upcoming earnings dates, alon

Tone
Positive 67/100
Event
Earnings
Published
26 Jun 2026 17:39
Source
TradingView
TradingView Direct company coverage

Verrica Pharmaceuticals Inc. Actuals & Estimates (NASDAQ:VRCA)

This article provides an overview of Verrica Pharmaceuticals Inc. (NASDAQ:VRCA), including its current stock price, market capitalization, and historical performance. It also details analyst forecasts for VRCA's future price, recent earnings, revenue figures, and upcoming earning

Tone
Positive 60/100
Event
Earnings
Published
26 Jun 2026 15:11
Source
TradingView
TradingView Direct company coverage

1NE0 Forecast — Price Target — Prediction for 2027

This article provides a forecast and price target for Verrica Pharmaceuticals Inc. (1NE0) stock, based on analyst opinions. It includes details on the stock's highest and lowest prices, upcoming earnings reports, and financial metrics like EPS, revenue, EBITDA, and net income. Ad

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 06:39
Source
TradingView
TradingView Direct company coverage

Verrica Pharmaceuticals Inc. Actuals & Estimates (SWB:1NE0)

This article provides an overview of Verrica Pharmaceuticals Inc.'s financial actuals and analyst estimates for the SWB:1NE0 stock. It details past earnings and revenue, future earnings report dates, stock price forecasts from analysts, and key financial metrics like EBITDA and e

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 03:09
Source
TradingView
TradingView Direct company coverage

A41A98 Forecast — Price Target — Prediction for 2027

This article provides a forecast and price target for Verrica Pharmaceuticals Inc. (A41A98), discussing analyst ratings, recent stock performance, and financial data. It includes details on revenue, earnings, market capitalization, and upcoming earnings reports, alongside frequen

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 00:41
Source
TradingView
The Dermatology Digest Direct company coverage

Milestone Alert: First US Patient Dosed in the Second Phase 3 Trial of Verrica’s YCANTH for Common Warts

Verrica Pharmaceuticals Inc. has dosed the first US patient in its second Phase 3 clinical trial (COVE-3) for YCANTH (VP-102) to treat common warts, with its Japanese partner Torii Pharmaceutical Co. also dosing the first Japanese patient. This marks a significant step towards se

Tone
Positive 71/100
Event
Market update
Published
23 Jun 2026 15:22
Source
The Dermatology Digest